BiTEs function by forming a bridge between T cells and cancer cells. The binding domain specific to the cancer antigen attaches to the malignant cell, while the CD3-binding domain attaches to the T cell. This proximity enables the T cell to recognize, attack, and kill the cancer cell. Essentially, BiTEs harness the cytotoxic power of T cells to induce targeted cell death.
